[
  {
    "id": 231,
    "question": "Patient with weakness hemianesthesia and tongue deviation (? medial medullary syndrome):",
    "option_a": "Vertebral artery",
    "option_b": "Anterior spinal artery (was not in options)",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nMedial medullary syndrome, also known as Dejerine syndrome, is a brainstem stroke syndrome characterized by a triad of contralateral motor deficits, contralateral loss of proprioception/tactile sensation, and ipsilateral tongue deviation. The syndrome is most classically attributed to infarction in the territory supplied by the anterior spinal artery.\n\n**Pathophysiology**\n\nThe medial medulla is supplied primarily by the anterior spinal artery, a branch arising from the vertebral arteries. Occlusion of this vessel leads to infarction of structures in the medial medulla including the pyramids (causing weakness), medial lemniscus (affecting sensation), and the hypoglossal nerve nucleus (resulting in tongue deviation).\n\n**Clinical Correlation**\n\nClinically, patients typically present with contralateral hemiparesis and hemisensory loss along with tongue deviation toward the side of the lesion. This constellation of signs helps differentiate medial medullary syndrome from other brainstem strokes such as lateral medullary (Wallenberg) syndrome.\n\n**Diagnostic Approach**\n\nBrain MRI with diffusion-weighted imaging is the modality of choice to identify medullary infarcts. To differentiate medial medullary syndrome from other brainstem strokes, vascular imaging (CTA or MRA) can be employed to assess the vertebral and anterior spinal arteries. Differential diagnoses include lateral medullary syndrome and pontine strokes, which have different clinical and imaging features.\n\n**Management Principles**\n\nThe management of medial medullary syndrome involves standard acute ischemic stroke protocols including potential thrombolysis, antiplatelet therapy thereafter, and aggressive risk factor management (e.g., controlling hypertension, dyslipidemia). In pregnant or lactating patients, treatment must be balanced with safety concerns, and nonpharmacologic measures or medications with established safety profiles in pregnancy should be considered.\n\n**Option Analysis**\n\nOption B (Anterior spinal artery) is considered correct because infarction in medial medullary syndrome is most commonly due to occlusion of the anterior spinal artery. Option A (Vertebral artery) is less specific \u2013 although the vertebral artery gives rise to the anterior spinal artery, the classic lesion localizes to the territory of the anterior spinal artery rather than from a direct vertebral artery occlusion.\n\n**Clinical Pearls**\n\n1) Medial medullary syndrome typically presents with contralateral hemiparesis and hemisensory loss with ipsilateral tongue weakness. 2) The anterior spinal artery, often a branch of the vertebral artery, is the vessel most commonly implicated in this syndrome.\n\n**Current Evidence**\n\nRecent MRI-based studies and advanced vascular imaging have reinforced the role of the anterior spinal artery in medial medullary syndrome. Guidelines continue to advocate for rapid imaging and tailored management strategies in brainstem strokes.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 232,
    "question": "Long scenario for patient with obesity and HTN and high BMI asking about best way for stroke prevention, vital signs and labs provided showed high b/p and hba1c around 6.9. And he is taking ant HTN and statin but not any dm medication:",
    "option_a": "Perindopril",
    "option_b": "Metformin",
    "option_c": "Or weight reduction",
    "option_d": "Aspirin",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nStroke prevention in patients with multiple risk factors (such as obesity and hypertension) is most effectively achieved through a multifactorial approach that focuses on modifiable lifestyle factors. In a patient already on antihypertensive and statin medication with borderline glycemic control (HbA1c ~6.9), weight reduction can significantly reduce overall stroke risk.\n\n**Pathophysiology**\n\nObesity contributes to a pro-inflammatory state, insulin resistance, dyslipidemia, and increased blood pressure\u2014all of which favor atherosclerosis and increase the risk of stroke. Weight reduction has been shown to improve these metabolic parameters and reduce vascular inflammation.\n\n**Clinical Correlation**\n\nPatients with obesity and hypertension are at an elevated risk for stroke due not only to high blood pressure but also because obesity worsens other metabolic risk factors. Weight reduction, therefore, becomes a central pillar of primary stroke prevention in such individuals.\n\n**Diagnostic Approach**\n\nA thorough clinical assessment including vital signs, laboratory studies (such as HbA1c, fasting glucose, and lipid profile), and measurement of BMI is key for risk stratification. Differential diagnoses for stroke prevention strategies could include adjustments in antihypertensive regimes or initiation of diabetes medications, but lifestyle modification remains universally recommended as first-line.\n\n**Management Principles**\n\nThe first-line management for such a patient is lifestyle modification\u2014with weight reduction being paramount. This includes dietary changes, increased physical activity, and sometimes structured weight loss programs. While continuing antihypertensives and statins is essential, adding medications like metformin is reserved for established type 2 diabetes mellitus. Aspirin is not routinely recommended for primary prevention in all patients due to bleeding risks. In pregnancy and lactation, lifestyle modifications are especially prioritized to avoid medication side effects.\n\n**Option Analysis**\n\nOption C (Weight reduction) is the best answer since it addresses the root modifiable risk factor. Option A (Perindopril) is already part of his antihypertensive regimen and further intensification would depend on blood pressure targets. Option B (Metformin) is not indicated unless he meets criteria for diabetes. Option D (Aspirin) has a limited role in primary prevention due to potential bleeding risks and is not the most effective choice here.\n\n**Clinical Pearls**\n\n1) Lifestyle modification, especially weight reduction, is the cornerstone of primary stroke prevention in obese patients. 2) Optimizing modifiable risk factors (hypertension, hyperglycemia, dyslipidemia) can significantly reduce stroke risk.\n\n**Current Evidence**\n\nCurrent guidelines emphasize the importance of a multifactorial approach to stroke prevention, with weight reduction being a key intervention. Recent studies have also highlighted the benefits of lifestyle modifications on cardiovascular outcomes, and these recommendations remain applicable in special populations (e.g., pregnant or lactating individuals) to minimize medication exposure when possible.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 233,
    "question": "A woman presented with acute left sided weakness and dysarthria a right ICH was found on CT (image shown without mentioning the diagnosis) patient vital signs as follows BP 167 systolic, what is the most appropriate management:",
    "option_a": "labetalol",
    "option_b": "factor 7 infusion",
    "option_c": "referral for NS for (minimally invasive?) evacuation",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAcute intracerebral hemorrhage (ICH) requires immediate management to prevent further bleeding and secondary brain injury. The core principle is to stabilize the patient by controlling blood pressure, which can reduce hematoma expansion and improve outcomes.\n\n**Pathophysiology**\n\nIn ICH, a ruptured cerebral vessel causes blood to accumulate within the brain parenchyma. Elevated blood pressure increases hydrostatic pressure on the vulnerable vessel walls, risking continued bleeding and hematoma enlargement. Controlling blood pressure minimizes further vessel disruption and secondary damage.\n\n**Clinical Correlation**\n\nA patient presenting with acute left-sided weakness and dysarthria, in the context of a right-sided hemorrhage on CT, reflects the neurological deficits caused by mass effect and neuronal injury. The moderately elevated systolic pressure (167 mm Hg) is significant enough in this setting to justify immediate antihypertensive therapy.\n\n**Diagnostic Approach**\n\nThe gold standard in the acute setting is a non-contrast CT scan to identify ICH. Differential diagnoses include ischemic stroke (which typically shows no blood on the CT scan), subarachnoid hemorrhage (which has a different distribution on imaging), and stroke mimics such as tumors or seizures. Rapid imaging confirms the diagnosis, guiding early management.\n\n**Management Principles**\n\nFirst-line management involves aggressive yet controlled blood pressure reduction using IV agents. Labetalol is a common first-line agent because of its rapid action and easy titration. Second-line approaches include using agents like nicardipine if labetalol is contraindicated. Neurosurgical intervention is reserved for cases with mass effect, imminent herniation, or specific locations (e.g., cerebellar hemorrhage). In pregnant and lactating patients, labetalol is also the antihypertensive of choice due to its well\u2010established safety profile in these populations.\n\n**Option Analysis**\n\nOption A (labetalol) is correct because it is effective in controlling blood pressure in the acute ICH setting. Option B (factor 7 infusion) is not indicated; recombinant activated factor VII has been studied in hemorrhage but is associated with thrombotic risks and is not standard care in ICH. Option C (referral for neurosurgery for evacuation) is typically reserved for selected cases (e.g., cerebellar hemorrhages or those with significant mass effect) and is not the immediate priority in a patient with modest blood pressure elevation and a spontaneous ICH.\n\n**Clinical Pearls**\n\n\u2022 Rapid blood pressure control is a cornerstone in preventing hematoma expansion in ICH.\n\u2022 Labetalol is safe and effective, including in pregnant and lactating patients.\n\u2022 Neurosurgical intervention is indicated only in select cases, not as the primary immediate treatment.\n\n**Current Evidence**\n\nRecent trials such as INTERACT2 and ATACH-II support early and aggressive blood pressure lowering in ICH. The AHA/ASA guidelines recommend similar approaches, and labetalol remains a preferred agent due to its safety profile and efficacy.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 234,
    "question": "Scenario about TIA management:",
    "option_a": "Dual antiplatelet",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nTransient ischemic attack (TIA) represents a temporary period of cerebral ischemia without permanent infarction. The primary goal is stroke prevention, and dual antiplatelet therapy (DAPT) has been shown to reduce early recurrent stroke risk in high-risk or minor TIA patients.\n\n**Pathophysiology**\n\nTIAs typically result from transient thromboembolic events that temporarily interrupt cerebral blood flow. Platelet aggregation plays a crucial role in clot propagation, and using two antiplatelet agents can interrupt this process, reducing the risk of full-blown stroke.\n\n**Clinical Correlation**\n\nPatients with TIA often have transient symptoms that resolve completely yet signal an increased risk for future stroke. Prompt initiation of therapy is thus essential to reduce this high early risk.\n\n**Diagnostic Approach**\n\nDiagnosis involves a careful clinical history and supportive imaging (brain CT or MRI) to rule out acute infarction. Differential diagnoses include migraine with aura, seizures, and other non-vascular events. Risk stratification scores, such as the ABCD2 score, help assess the risk of stroke following a TIA.\n\n**Management Principles**\n\nFirst-line treatment for high-risk TIA typically involves dual antiplatelet therapy (e.g., aspirin plus clopidogrel) for a short course (typically 21\u201390 days) based on evidence from the CHANCE and POINT trials. Subsequent management includes long-term single antiplatelet therapy, risk factor modification (such as blood pressure and cholesterol control), and lifestyle changes. In pregnancy, low-dose aspirin is generally considered safe, but clopidogrel has less robust data; decisions should weigh risks versus benefits carefully. In lactating patients, aspirin at low doses is acceptable, though caution with clopidogrel is advised.\n\n**Option Analysis**\n\nOption A (Dual antiplatelet therapy) is correct as studies have demonstrated its efficacy in reducing early recurrent stroke risk in TIA patients. Although other options exist (such as single antiplatelet therapy, anticoagulation, or immediate statin therapy), the evidence clearly supports short-term DAPT in patients with high-risk TIA.\n\n**Clinical Pearls**\n\n\u2022 TIA is a critical warning sign for stroke; prompt DAPT can significantly reduce recurrence risk.\n\u2022 The CHANCE and POINT trials established the role of DAPT in the early management of TIA.\n\u2022 Risk factor modification remains an essential part of long-term stroke prevention.\n\n**Current Evidence**\n\nRecent guidelines, supported by the CHANCE and POINT trials, advise the use of dual antiplatelet therapy for a limited period immediately following a high-risk TIA to reduce early recurrent stroke risk.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 235,
    "question": "Scenario about a patient with A.COM aneurysm, which of the following factor is the most predictive of aneurysm rupture:",
    "option_a": "Size",
    "option_b": "Acom location less likely to rupture",
    "option_c": "Uncontrolled b/p",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nRisk stratification in patients with intracranial aneurysms involves identifying features that most strongly predict rupture. Aneurysm size remains a critical factor in many validated scoring systems and risk models.\n\n**Pathophysiology**\n\nThe rupture of an aneurysm is primarily due to hemodynamic stress and wall weakening. Larger aneurysms have increased wall tension, making them more susceptible to rupture. Other factors, such as location and uncontrolled hypertension, also contribute, but size is often the primary measurable predictor.\n\n**Clinical Correlation**\n\nAneurysms located at the anterior communicating (ACOM) artery carry an inherently higher risk of rupture even when they are small. However, the overall risk of rupture increases in correlation with aneurysm size, which is used to guide the decision towards surgical or endovascular repair.\n\n**Diagnostic Approach**\n\nImaging tests, including CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA), are used to evaluate aneurysm size, shape, and location. Differential diagnoses include pseudoaneurysms or vascular malformations. Detailed imaging is necessary to discern the rupture risk and plan management.\n\n**Management Principles**\n\nManagement is tiered: small, low-risk aneurysms may be observed with serial imaging, while larger aneurysms (or those with concerning features) are managed with surgical clipping or endovascular coiling. Aggressive blood pressure control is important in all patients. In pregnant or lactating patients, treatment plans are individualized; non-ionizing imaging modalities and careful management of blood pressure and anesthesia risks are prioritized.\n\n**Option Analysis**\n\nOption A (Size) is correct because numerous studies and risk scoring systems (like PHASES) underscore aneurysm size as the most predictive factor of rupture. Option B is incorrect because aneurysms in the anterior communicating artery are known to have a higher rupture risk rather than being 'less likely' to rupture. Option C (Uncontrolled blood pressure), while a modifiable risk factor for rupture, is less predictive than the inherent structural feature of aneurysm size.\n\n**Clinical Pearls**\n\n\u2022 Aneurysm size is a key criterion in determining rupture risk; aneurysms above certain thresholds (e.g., >7 mm) are higher risk.\n\u2022 ACOM aneurysms are particularly dangerous and may rupture even at smaller sizes.\n\u2022 Integrating size with other factors (such as morphology and location) improves risk stratification.\n\n**Current Evidence**\n\nRecent systematic reviews and updated scoring systems continue to emphasize the predictive value of aneurysm size. The PHASES score remains a widely used tool in clinical practice, alongside emerging research that refines risk prediction models.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 236,
    "question": "Patient with sickle cell anemia wants to check on himself because his brother is also sickler and had previous stroke. How to predict:",
    "option_a": "Transcranial doppler",
    "option_b": "CTA",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn patients with sickle cell disease (SCD), the risk of cerebrovascular complications including stroke is significantly heightened. Transcranial Doppler (TCD) ultrasound is the validated screening tool designed to measure cerebral blood flow velocities, which are correlated with stroke risk.\n\n**Pathophysiology**\n\nSickle cell anemia leads to chronic endothelial injury and vasculopathy, resulting in arterial stenosis. As vessels narrow, blood flow velocity increases, which can be detected by TCD. Elevated velocities indicate a compensatory mechanism for reduced lumen diameter and predict an increased risk of ischemic stroke.\n\n**Clinical Correlation**\n\nScreening with TCD is particularly important in children with SCD, as early identification of abnormal flow velocities allows for timely intervention (e.g., chronic transfusion therapy) to reduce stroke risk. Even in adult patients, TCD may help in risk assessment if there is a concerning family or personal history of stroke.\n\n**Diagnostic Approach**\n\nTCD is non-invasive, cost-effective, and has no radiation exposure, making it ideal for repeated screening. Alternative imaging (such as CTA or MRA) may further delineate vascular anatomy but are not used for routine screening due to risks associated with radiation and contrast use.\n\n**Management Principles**\n\nIf TCD screening reveals elevated cerebral blood flow velocities, the first-line management is typically the initiation of a chronic red cell transfusion program to reduce the risk of stroke. Hydroxyurea is another option that may be used to reduce sickling. In pregnant or lactating patients, careful management is needed to balance the benefits of transfusion therapy with potential complications, and non-ionizing imaging like TCD remains the preferred screening modality.\n\n**Option Analysis**\n\nOption A (Transcranial Doppler) is correct because it is the standard, widely recommended screening tool for predicting stroke risk in individuals with sickle cell disease. Option B (CTA) is less favored due to the exposure to radiation and contrast agents, and it is not validated as a screening tool in this population.\n\n**Clinical Pearls**\n\n\u2022 TCD screening in children with sickle cell disease has significantly reduced the incidence of first strokes.\n\u2022 Elevated cerebral blood flow velocities on TCD are a strong predictor of stroke risk.\n\u2022 TCD is safe for repeated use and is especially valuable in the pediatric population.\n\n**Current Evidence**\n\nSeminal trials such as STOP and STOP II have validated the use of TCD screening to identify high-risk patients and guide preventative interventions. Current guidelines continue to recommend TCD as the cornerstone screening tool for stroke prevention in sickle cell disease.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 237,
    "question": "Scenario of stroke with normal CT what do next (not thrombolysis):",
    "option_a": "CTA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn the acute stroke setting, a non-contrast CT scan is typically the first imaging modality used to exclude hemorrhage. However, early in ischemic stroke, CT may appear normal due to the time lag before radiographic changes become evident. Thus, vascular imaging such as CT angiography (CTA) is critical to evaluate the cerebral vessels for occlusions or stenoses, especially when thrombolysis isn\u2019t an option.\n\n**Pathophysiology**\n\nIschemic strokes result from an interruption of blood flow, often due to an occlusive thrombus or embolus. In the hyperacute phase, cytotoxic edema has not yet produced clear changes on CT. CTA, by visualizing the cerebral vasculature, can detect large vessel occlusions which underlie the infarct and help determine patient eligibility for interventions such as thrombectomy.\n\n**Clinical Correlation**\n\nPatients presenting with clinical signs of stroke may have a normal CT scan if imaged very early. CTA is then utilized to assess for large vessel occlusions that may not be evident on non-contrast CT, guiding further management decisions. Recognizing that a normal CT can be misleading is key to timely diagnosis and treatment.\n\n**Diagnostic Approach**\n\nThe differential diagnosis includes transient ischemic attack (TIA), migraine with aura, and other conditions mimicking stroke. The diagnostic approach generally begins with a non-contrast CT to exclude hemorrhage, followed by CTA or CT perfusion studies to evaluate ischemic tissue and vascular status.\n\n**Management Principles**\n\nCurrent guidelines recommend rapid imaging in suspected stroke. When CT is normal in a patient with stroke symptoms, a CTA is indicated to identify occlusions that could be amenable to endovascular therapy. In patients who are pregnant or lactating, the benefits of CTA (with appropriate shielding) outweigh the risks, as early detection and intervention are critical.\n\n**Option Analysis**\n\nOption A (CTA) is correct because it offers detailed visualization of the cerebral arteries. The other options are not provided, but among available choices, CTA is the most appropriate next investigation when the initial non-contrast CT is normal.\n\n**Clinical Pearls**\n\n1. A normal CT in the hyperacute phase does not exclude ischemic stroke. 2. CTA is essential for diagnosing large vessel occlusion. 3. Rapid vascular imaging guides potential subsequent interventions.\n\n**Current Evidence**\n\nRecent AHA/ASA guidelines emphasize the role of CTA in the early evaluation of ischemic stroke, particularly when CT findings are inconclusive and large vessel occlusion is suspected. Studies support that CTA enables rapid decision-making for possible endovascular therapy.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 238,
    "question": "Scenario about Wernicke aphasia which artery:",
    "option_a": "Inferior division of MCA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nWernicke\u2019s aphasia is characterized by impaired language comprehension paired with fluent but often nonsensical speech. It results from damage to the language processing center, typically located in the posterior portion of the superior temporal gyrus.\n\n**Pathophysiology**\n\nWernicke\u2019s area is predominantly supplied by the inferior division of the middle cerebral artery (MCA) in the dominant hemisphere\u2014most often the left. Occlusion or infarction in this region disrupts language comprehension while sparing speech fluency, producing the classical picture of Wernicke\u2019s aphasia.\n\n**Clinical Correlation**\n\nClinically, patients with Wernicke\u2019s aphasia present with fluent speech that may include paraphasias and neologisms, along with significant comprehension deficits. Recognizing the vascular territory affected helps correlate the clinical syndrome with its underlying vascular pathology.\n\n**Diagnostic Approach**\n\nThe differential diagnosis includes other aphasic syndromes such as Broca\u2019s aphasia, conduction aphasia, and transcortical sensory aphasia. Neuroimaging (typically MRI with appropriate sequences) confirms the infarct location and its vascular distribution.\n\n**Management Principles**\n\nManagement of stroke affecting Wernicke\u2019s area follows standard ischemic stroke protocols, including considerations for thrombolysis or thrombectomy if within the treatment window. For pregnant or lactating patients, similar stroke protocols apply with adjustments to imaging and medication selection. Subsequent rehabilitation with speech and language therapy is crucial.\n\n**Option Analysis**\n\nOption A (Inferior division of MCA) is correct because this artery supplies Wernicke\u2019s area. Other options, though not listed here, do not accurately correspond to the vascular supply of the language comprehension center.\n\n**Clinical Pearls**\n\n1. Wernicke's aphasia presents with fluent but nonsensical speech and impaired comprehension. 2. It is most commonly due to infarction in the territory of the inferior division of the left MCA. 3. Detailed neuroimaging is essential to confirm the lesion\u2019s location.\n\n**Current Evidence**\n\nCurrent neuroimaging studies and stroke guidelines consistently affirm that the inferior division of the MCA supplies Wernicke's area. Emerging research continues to refine our understanding of aphasia subtypes and optimal rehabilitation strategies.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 239,
    "question": "Patient with Sickle Cell Anemia who with symptoms of infarction, in investigation he was found to have severe intracranial MCA stenosis what would you do",
    "option_a": "ASA",
    "option_b": "Stenting",
    "option_c": "DAPT",
    "option_d": "Exchange transfusion",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nPatients with sickle cell disease (SCD) are at increased risk for cerebrovascular complications, including stroke. The underlying hemoglobinopathy leads to chronic hemolysis and vaso-occlusion, predisposing patients to both infarcts and vascular stenoses.\n\n**Pathophysiology**\n\nIn SCD, repeated sickling episodes cause endothelial damage and intimal hyperplasia, resulting in vascular stenosis or occlusion. Severe intracranial stenosis, particularly in the middle cerebral artery (MCA), can precipitate cerebral infarction due to impaired blood flow. Exchange transfusion reduces the proportion of abnormal hemoglobin (HbS) and improves oxygen delivery.\n\n**Clinical Correlation**\n\nClinically, SCD patients presenting with stroke symptoms and evidence of intracranial stenosis require prompt treatment to prevent further ischemic injury. Exchange transfusion is the frontline therapy aimed at reducing HbS levels while minimizing blood viscosity and the risk of further vaso-occlusive events.\n\n**Diagnostic Approach**\n\nDifferential diagnoses in this context include thrombotic stroke due to other causes (like cardioembolism or atherosclerosis) and vasculitic processes. Neuroimaging (MRI/MRA) combined with a thorough hematologic evaluation helps differentiate SCD-related stroke from other etiologies.\n\n**Management Principles**\n\nThe current standard of care for an SCD patient with stroke involves urgent exchange transfusion, which rapidly decreases the HbS concentration and reduces ongoing ischemia. This is supported by guidelines and studies (such as the STOP trials) and is considered first-line therapy. In pregnancy and lactation, transfusion therapy remains the mainstay, with careful monitoring and matched blood products to avoid alloimmunization and other complications.\n\n**Option Analysis**\n\nOption D (Exchange transfusion) is correct because it directly addresses the underlying sickling and vaso-occlusion process by reducing HbS levels. Option A (ASA) is not sufficient for the acute management of SCD stroke; Option B (Stenting) and Option C (DAPT) have not been shown to be effective or safe primary treatments in this unique patient population.\n\n**Clinical Pearls**\n\n1. SCD increases the risk of stroke due to repeated vascular injury. 2. Exchange transfusion is critical in rapidly reducing pathological HbS levels during an acute stroke. 3. Chronic transfusion therapy may be required for secondary stroke prevention.\n\n**Current Evidence**\n\nRecent updates and clinical trials (including the STOP trial series) reinforce exchange transfusion as the primary intervention in SCD-related stroke. Guidelines from hematology and neurology societies emphasize rapid reduction of HbS via exchange transfusion to mitigate further ischemic injury.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "id": 240,
    "question": "Scenario about CVT what will confirm diagnosis:",
    "option_a": "CTV",
    "option_b": "If mri choose it",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nCerebral venous thrombosis (CVT) is a condition where thrombus formation in the cerebral venous sinuses leads to impaired cerebral venous drainage. Its clinical presentation can be subtle and variable, making imaging critical for confirmation.\n\n**Pathophysiology**\n\nIn CVT, thrombus formation within the cerebral venous system results in venous congestion, increased intracranial pressure, and potentially venous infarctions or hemorrhages. The disruption of normal venous drainage may be due to hypercoagulable states, infections, or other risk factors.\n\n**Clinical Correlation**\n\nPatients with CVT often present with headache, focal neurological deficits, seizures, or signs of increased intracranial pressure such as papilledema. Accurate diagnosis is essential to initiate appropriate anticoagulation therapy and prevent complications.\n\n**Diagnostic Approach**\n\nThe differential diagnosis for CVT includes intracerebral hemorrhage, arterial ischemic stroke, and benign intracranial hypertension. MRI with MR venography (MRV) is typically the modality of choice because of its high sensitivity and specificity, while CT venography (CTV) is a reasonable alternative when MRI is unavailable.\n\n**Management Principles**\n\nOnce diagnosed, the mainstay of treatment for CVT is anticoagulation, typically initiated with heparin (unfractionated or low-molecular-weight) even in the presence of hemorrhage. For pregnant or lactating patients, low-molecular-weight heparin is preferred due to its safety profile. Long-term management may include oral anticoagulants. Confirmatory imaging with MRI/MRV guides these decisions.\n\n**Option Analysis**\n\nOption B (If MRI choose it) is interpreted as advocating for an MRI-based approach (typically MRI with MR venography), which is the preferred modality for confirming CVT given its superior soft-tissue contrast and ability to directly visualize the thrombus. Option A (CTV) is also acceptable but is generally considered second-line when MRI is accessible.\n\n**Clinical Pearls**\n\n1. CVT can present with nonspecific symptoms, making advanced imaging essential. 2. MRI with MR venography is the gold standard for diagnosing CVT. 3. Early anticoagulation improves outcomes in CVT even when a hemorrhagic component is present.\n\n**Current Evidence**\n\nLatest guidelines by the AHA/ASA and various neuroimaging consensus statements highlight that MRI with MRV is the confirmatory imaging of choice for CVT due to its high sensitivity and absence of radiation, although CT venography remains a good alternative in settings where MRI is not feasible.",
    "exam_year": "2020",
    "exam_type": "Part II"
  }
]